AD/PD 2022 | Blood-based biomarkers for Alzheimer’s disease screening

The availability of a blood biomarker for the diagnosis of Alzheimer’s disease is highly anticipated. Giovanni Frisoni, MD, University of Geneva, Geneva, Switzerland, discusses how blood-based biomarkers will be used in clinical practice. Although initial research focused on using such biomarkers for the diagnosis of Alzheimer’s disease, data available indicates that blood-based biomarkers could be used as a screening tool. If a screening test becomes available only if the test results are abnormal, further testing, such as PET scans and lumbar punctures, would be needed. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.